Zobrazit více v PubMed
Gundert‐Remy U, Bernauer U, Blomeke B, et al. Extrahepatic metabolism at the body's internal‐external interfaces. Drug Metab Rev. 2014; 46:291–324.
PubMed
Sutter CH, Yin H, Li Y, et al. EGF receptor signaling blocks aryl hydrocarbon receptor‐mediated transcription and cell differentiation in human epidermal keratinocytes. PNAS. 2009; 106:4266–4271.
PubMed
PMC
Kiriluk KJ, Prasad SM, Patel AR, Steinberg GD, Smith ND. Bladder cancer risk from occupational and environmental exposures. Urol Oncol. 2012; 30:199–211.
PubMed
Rendic S, Guengerich FP. Contributions of human enzymes in carcinogen metabolism. Chem Res Toxicol. 2012; 25:1316–1383.
PubMed
PMC
Figueroa JD, Malats N, Garcia‐Closas M, et al. Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis. 2008; 29:1955–1962.
PubMed
PMC
Grando JP, Kuasne H, Losi‐Guembarovski R, et al. Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancer. Clin Exp Med. 2009; 9:21–28.
PubMed
Alexandrov LB, Nik‐Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013; 500:415–421.
PubMed
PMC
Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. Jama. 2011; 306:737–745.
PubMed
PMC
Haugen A, Becher G, Benestad C, et al. Determination of polycyclic aromatic hydrocarbons in the urine, benzo(a)pyrene diol epoxide‐DNA adducts in lymphocyte DNA, and antibodies to the adducts in sera from coke oven workers exposed to measured amounts of polycyclic aromatic hydrocarbons in the work atmosphere. Cancer Res. 1986; 46:4178–4183.
PubMed
Benhamou S, Laplanche A, Guillonneau B, et al. DNA adducts in normal bladder tissue and bladder cancer risk. Mutagenesis. 2003; 18:445–448.
PubMed
Sulc M, Indra R, Moserova M, et al. The impact of individual cytochrome P450 enzymes on oxidative metabolism of benzo[a]pyrene in human livers. Environ Mol Mutagen. 2016; 57:229–235.
PubMed
PMC
Nebert DW, Shi Z, Galvez‐Peralta M, Uno S, Dragin N. Oral benzo[a]pyrene: understanding pharmacokinetics, detoxication, and consequences‐Cyp1 knockout mouse lines as a paradigm. Mol. Pharmacol. 2013; 84:304–313.
PubMed
PMC
El‐Serafi I, Afsharian P, Moshfegh A, Hassan M, Terelius Y. Cytochrome P450 oxidoreductase influences CYP2B6 activity in cyclophosphamide bioactivation. PLoS ONE. 2015; 10:e0141979.
PubMed
PMC
Arlt VM, Stiborova M, Henderson CJ, et al. Metabolic activation of benzo[a]pyrene in vitro by hepatic cytochrome P450 contrasts with detoxification in vivo: experiments with hepatic cytochrome P450 reductase null mice. Carcinogenesis. 2008; 29:656–665.
PubMed
Iyanagi T, Xia C, Kim JJ. NADPH‐cytochrome P450 oxidoreductase: prototypic member of the diflavin reductase family. Arch Biochem Biophys. 2012; 528:72–89.
PubMed
PMC
Xiao X, Ma G, Li S, et al. Functional POR A503V is associated with the risk of bladder cancer in a Chinese population. Sci Rep. 2015; 5:11751.
PubMed
PMC
Vanderslice RR, Boyd JA, Eling TE, Philpot RM. The cytochrome P‐450 monooxygenase system of rabbit bladder mucosa: enzyme components and isozyme 5‐dependent metabolism of 2‐aminofluorene. Cancer Res. 1985; 45:5851–5858.
PubMed
Guhe C, Degen GH, Schuhmacher US, Kiefer F, Follmann W. Drug metabolizing enzyme activities in porcine urinary bladder epithelial cell cultures (PUBEC). Arch Toxicol. 1996; 70:599–606.
PubMed
Rheinwald JG, O'Connell TM. Intermediate filament proteins as distinguishing markers of cell type and differentiated state in cultured human urinary tract epithelia. Ann NY Acad Sci. 1985; 455:259–267.
PubMed
Baker SC, Shabir S, Southgate J. Biomimetic urothelial tissue models for the in vitro evaluation of barrier physiology and bladder drug efficacy. Mol Pharm. 2014; 11:1964–1970.
PubMed
Southgate J, Hutton KA, Thomas DF, Trejdosiewicz LK. Normal human urothelial cells in vitro: proliferation and induction of stratification. Lab Invest. 1994; 71:583–594.
PubMed
Cross WR, Eardley I, Leese HJ, Southgate J. A biomimetic tissue from cultured normal human urothelial cells: analysis of physiological function. Am J Physiol Renal Physiol. 2005; 289:F459–F468.
PubMed
Booth C, Harnden P, Trejdosiewicz LK, Scriven S, Selby PJ, Southgate J. Stromal and vascular invasion in an human in vitro bladder cancer model. Lab Invest. 1997; 76:843–857.
PubMed
van Oers JM, Wild PJ, Burger M, et al. FGFR3 mutations and a normal CK20 staining pattern define low‐grade noninvasive urothelial bladder tumours. Eur Urol. 2007; 52:760–768.
PubMed
Wittekind C. [2010 TNM system: on the 7th edition of TNM classification of malignant tumors]. Pathologe. 2010; 31:331–332.
PubMed
Otto W, Denzinger S, Fritsche HM, et al. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int. 2011; 107:404–408.
PubMed
Southgate J, Varley CL, Garthwaite MA, et al. Differentiation potential of urothelium from patients with benign bladder dysfunction. BJU Int. 2007; 99:1506–1516.
PubMed
PMC
Smith GC, Tew DG, Wolf CR. Dissection of NADPH‐cytochrome P450 oxidoreductase into distinct functional domains. PNAS. 1994; 91:8710–8714.
PubMed
PMC
Wohak LE, Krais AM, Kucab JE, et al. Carcinogenic polycyclic aromatic hydrocarbons induce CYP1A1 in human cells via a p53‐dependent mechanism. Arch Toxicol. 2016; 90:291–304.
PubMed
PMC
Divi RL, Luch A, Verma M, Mahadevan B. CYP1B1 detection. Curr Protoc Toxicol. 2012; Chapter 4:Unit 4:38.
PubMed
Phillips DH, Arlt VM. (32)P‐postlabeling analysis of DNA adducts. Methods Mol Biol. 2014; 1105:127–138.
PubMed
Kucab JE, van Steeg H, Luijten M, et al. TP53 mutations induced by BPDE in Xpa‐WT and Xpa‐Null human TP53 knock‐in (Hupki) mouse embryo fibroblasts. Mutat Res. 2015; 773:48–62.
PubMed
PMC
Dadhania V, Zhang M, Zhang L, et al. Meta‐analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine. 2016; 12:105–117.
PubMed
PMC
Shimada T, Gillam EM, Sutter TR, Strickland PT, Guengerich FP, Yamazaki H. Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997; 25:617–622.
PubMed
Sutherland M, Gill JH, Loadman PM, et al. Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder. Mol Cancer Ther. 2013; 12:27–37.
PubMed
Fichtner I, Monks A, Hose C, Stevens MF, Bradshaw TD. The experimental antitumor agents Phortress and doxorubicin are equiactive against human‐derived breast carcinoma xenograft models. Breast Cancer Res Treat. 2004; 87:97–107.
PubMed
Akama T, Shida Y, Sugaya T, Ishida H, Gomi K, Kasai M. Novel 5‐aminoflavone derivatives as specific antitumor agents in breast cancer. J Med Chem. 1996; 39:3461–3469.
PubMed
Hunter FW, Young RJ, Shalev Z, et al. Identification of P450 oxidoreductase as a major determinant of sensitivity to hypoxia‐activated prodrugs. Cancer Res. 2015; 75:4211–4223.
PubMed
Moore BP, Hicks RM, Knowles MA, Redgrave S. Metabolism and binding of benzo(a)pyrene and 2‐acetylaminofluorene by short‐term organ cultures of human and rat bladder. Cancer Res. 1982; 42:642–648.
PubMed
Stoner GD, Daniel FB, Schenck KM, Schut HA, Goldblatt PJ, Sandwisch DW. Metabolism and DNA binding of benzo[a]pyrene in cultured human bladder and bronchus. Carcinogenesis. 1982; 3:195–201.
PubMed
Chang TK, Chen J, Yang G, Yeung EY. Inhibition of procarcinogen‐bioactivating human CYP1A1, CYP1A2 and CYP1B1 enzymes by melatonin. J Pineal Res. 2010; 48:55–64.
PubMed
Alexandrov LB, Ju YS, Haase K, et al. Mutational signatures associated with tobacco smoking in human cancer. Science. 2016; 354:618–622.
PubMed
PMC
Adachi J, Mori Y, Matsui S, et al. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J Biol Chem. 2001; 276:31475–31478.
PubMed
Varley CL, Stahlschmidt J, Lee WC, et al. Role of PPARgamma and EGFR signalling in the urothelial terminal differentiation programme. J Cell Sci. 2004; 117:2029–2036.
PubMed
Cho YC, Zheng W, Yamamoto M, Liu X, Hanlon PR, Jefcoate CR. Differentiation of pluripotent C3H10T1/2 cells rapidly elevates CYP1B1 through a novel process that overcomes a loss of Ah Receptor. Arch Biochem Biophys. 2005; 439:139–153.
PubMed
Walsh AA, Szklarz GD, Scott EE. Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism. J Biol Chem. 2013; 288:12932–12943.
PubMed
PMC
Chopra B, Hinley J, Oleksiewicz MB, Southgate J. Trans‐species comparison of PPAR and RXR expression by rat and human urothelial tissues. Toxicol Pathol. 2008; 36:485–495.
PubMed